Tidemark’s Beam Therapeutics BEAM Stock Holding History

Tidemark’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.99K	Hold	58	–	–	﹤0.01%	695
2026 Q1	$1.38K	Buy	+58	New	+$1.61K	﹤0.01%	678

Other funds holding BEAM

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Tidemark's BEAM Position: Q2 2026 in Review

Tidemark held its Beam Therapeutics (BEAM) position steady in Q2 2026 at 58 shares worth $1.99K. The position accounts for ﹤0.01% of the portfolio, ranked #695.

Tidemark first reported a position in BEAM in Q1 2026 and has held it in 2 quarters since. 255 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Tidemark held 58 shares of Beam Therapeutics worth $1.99K as of Q2 2026.
Tidemark left its Beam Therapeutics share count unchanged in Q2 2026.
Beam Therapeutics made up ﹤0.01% of Tidemark's portfolio in Q2 2026, its #695 holding.
Tidemark first reported a position in Beam Therapeutics in Q1 2026 and has held it in 2 quarters since.
255 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Tidemark's 13F filing for Q2 2026, filed 10 Aug 2026.